Phuturdex › Diseases › Wounds and Injuries
Drugs in development · updated 30 October 2026
Wounds and Injuries: drugs in development
As of 30 October 2026 there are 25 active clinical trials (recruiting or ongoing, phases I–III) on 25 drugs for wounds and Injuries. 5 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PsilocybinPsilocybine | III | 2 | NCT07703722 |
| Interferon gamma | III | 1 | NCT05843786 |
| Allopregnanolone | II | 1 | NCT07079761 |
| PT150 | II | 1 | NCT07187011 |
| NG004 | I | 1 | NCT06817577 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| KetamineKetalar® | III | 2 | NCT05437575 |
| Acellular Tissue Engineered Vesselsymvess® | III | 1 | NCT07762313 |
| FentanylFentanyl Citrate Buccal Tablet, Subsys® | III | 1 | NCT05437575 |
| FinasteridePropecia®, Proscar® | II–III | 1 | NCT07742553 |
| MidazolamMidazolam Hydrochloride (Autoinjector)®, Midazolam In 0.8% Sodium Chloride® | III | 1 | NCT07113483 |
| RemimazolamByfavo® | III | 1 | NCT07113483 |
| TacrolimusEnvarsus XR, Prograf® | II–III | 1 | NCT02395497 |
| Testosterone cypionateAzmiro® | II–III | 1 | NCT07742553 |
| Tranexamic AcidTransexamic acid, Lysteda® | III | 1 | NCT04387305 |
| CannabidiolEpidiolex, Epidyolex® | I–II | 3 | NCT07278505 |
| Fampridine4-Aminopyridine, Dalfampridine | II | 2 | NCT06596434 |
| BimekizumabBimzelx® | II | 1 | NCT07767864 |
| BupivacaineExparel, Bupivacain | II | 1 | NCT06429501 |
| EpinephrineAdrenaline, Adrenalin® | II | 1 | NCT06429501 |
| EstradiolESTRING, Vagifem | II | 1 | NCT07868536 |
Sorted by most advanced phase and number of active trials. Showing 15 of 20 drugs.
All 25 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Traumatic brain injury 29 drugs
- Spinal cord injury 25 drugs
- Cardiotoxicity 21 drugs
- Pain 75 drugs
- Radiation Injuries 13 drugs
- Brain Injuries 11 drugs
- Concussion 10 drugs
- Bites and stings 15 drugs
- Burn 11 drugs
- Rotator cuff tear 7 drugs
- Breast neoplasm 593 drugs
- Chronic subdural hematoma 4 drugs
Broader categories
- Mental disorder 24 drugs
- Neurologic Manifestations 15 drugs
- Skin disease 34 drugs
- Skin and connective tissue diseases 3 drugs
- Ulcer 4 drugs
- Urogenital Diseases 16 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D014947 “Wounds and Injuries”.